Introduction: We aimed to determine whether anti-1-amino-3-F-fluorocyclobutane-1-carboxylic acid (F-fluciclovine) positron emission tomography/computed tomography (PET/CT) can accurately detect residual non-seminomatous germ cell tumor (NSGCT) prior to retroperitoneal lymph node dissection (RPLND). There is no reliable way to differentiate between fibrosis/necrosis, teratoma, and viable germ cell tumor in patients receiving post-chemotherapy RPLND. Functional imaging, including F-fludeoxyglucose (18F-FDG) PET/CT, has been disappointing. Due to the need for better imaging modalities, our prospective, pilot study aims to investigate the accuracy of F-fluciclovine PET/CT in detecting residual tumor prior to RPLND.
Methods: From March 2018 to May 2019, 10 eligible patients underwent preoperative F-fluciclovine PET/CT prior to undergoing bilateral, full-template RPLND or excision of mass (for one re-do RPLND) in a prospective, phase 2 study. Correlation between F-fluciclovine PET/CT and RPLND pathology were evaluated on a per-patient level.
Results: A total of 10 patients (mean age 29±7.6 years) underwent F-fluciclovine PET/CT prior to surgery. Nine of 10 patients received chemotherapy prior to RPLND. Correlation between F-fluciclovine PET/CT and RPLND pathology was seen in 3/10 (30%) patients. Five of 10 patients (50%) with negative F-fluciclovine PET/CT were found to have residual disease/teratoma on RPLND. Compared to the reference standard of RPLND, F-fluciclovine PET/CT demonstrated 29% sensitivity and 33% specificity. No patients experienced any adverse events due to F-fluciclovine PET/CT.
Conclusions: Despite a different mechanism of action from F-FDG, F-fluciclovine has low sensitivity and specificity for residual teratoma in the retroperitoneum.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923889 | PMC |
| http://dx.doi.org/10.5489/cuaj.7317 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[F]PSMA-1007 PET for biochemical recurrence of prostate cancer, a comparison with [F]Fluciclovine.
EJNMMI Rep
November 2024
Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Radboud Institute for Health Sciences, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.
Aim: The objective of this study was to compare the detection rates of [F]PSMA-1007 and [F]Fluciclovine in early biochemical recurrence (BCR) of prostate cancer, i.e. with low prostate-specific antigen (PSA) levels (0.
View Article and Find Full Text PDFThe role of brown adipose tissue in branched-chain amino acid clearance in people.
iScience
August 2024
Department of Radiology, University of California Davis, Sacramento, CA 95817, USA.
Brown adipose tissue (BAT) in rodents appears to be an important tissue for the clearance of plasma branched-chain amino acids (BCAAs) contributing to improved metabolic health. However, the role of human BAT in plasma BCAA clearance is poorly understood. Here, we evaluate patients with prostate cancer who underwent positron emission tomography-computed tomography imaging after an injection of F-fluciclovine (L-leucine analog).
View Article and Find Full Text PDFReal-world evidence of F-fluciclovine Positron emission tomography/computed tomography performance for recurrent prostate cancer in the Veterans Affairs Health System.
Prostate
October 2024
Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Background: There are no population-level studies assessing F-fluciclovine (fluciclovine) utilization of Positron emission tomography/computed tomography (PET/CT) for biochemically recurrent prostate cancer (PC). We assessed fluciclovine PET/CT in the Veterans Affairs Health Care System.
Methods: Of 1153 men with claims suggesting receipt of fluciclovine PET/CT, we randomly reviewed charts of 300 who indeed underwent fluciclovine PET/CT.
Prospective investigation of amino acid transport and PSMA-targeted positron emission tomography for metastatic lobular breast carcinoma.
Eur J Nucl Med Mol Imaging
November 2024
Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, NE, Atlanta, GA, 30322, USA.
Purpose: To explore the feasibility of imaging amino-acid transport and PSMA molecular pathways in the detection of metastatic breast invasive lobular carcinoma (ILC) and if there is superior detection compared to standard-of-care imaging [computed tomography (CT)/bone scan, or F-FDG positron-emission-tomography (PET)-CT].
Methods: 20 women with de-novo or suspected metastatic ILC underwent two PET-CT scans with F-fluciclovine and Ga-PSMA-11 on separate days. Uptake per patient and in 3 regions per patient - ipsilateral axillary lymph node (LN), extra-axillary LN (ipsilateral supraclavicular or internal mammary), or distant sites of disease - was compared to standard-of-care imaging (CT/bone scan in 13 patients and F-FDG PET-CT in 7 patients).
True-Positive F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study.
J Nucl Med
July 2024
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
Article Synopsis
- F-rhPSMA-7.3 (F-flotufolastat) is a diagnostic radiopharmaceutical used for PET imaging to identify prostate cancer lesions in patients with biochemical recurrence and negative conventional imaging.
- The SPOTLIGHT study evaluated the effectiveness of F-flotufolastat PET/CT by comparing results against histopathology and follow-up imaging to confirm findings.
- Results showed a detection rate of 95% and a verified detection rate of 64%, with notable true-positive lesions found in both the prostate bed and pelvic lymph nodes among the evaluated patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!